OKX Brings Magnificent 7 and Commodity Perps to EU
OKX expands X-Perps under MiCA, targeting EU retail traders with stock and commodity perpetuals.
OKX launched tokenized perpetual futures on Magnificent 7 stocks, gold, and oil for European retail traders as of June 2026, expanding its X-Perps product line under MiCA's regulated derivatives framework.
Why It Matters
European retail traders now have exchange-traded access to crypto-native perpetuals tracking assets like Apple, Nvidia, and Brent crude — without holding the underlying securities. According to CoinTelegraph, OKX is positioning this move directly against Coinbase, Kraken, and Binance in the EU regulated derivatives space. MiCA provides a cleaner compliance runway than pre-2025 patchwork national regimes, meaning products launched today carry more legal certainty for users. For retail participants, the key risk remains that perpetual futures — even on familiar equity names — carry liquidation exposure and funding-rate costs that traditional stock purchases do not.
Context
X-Perps are OKX's tokenized synthetic perpetual contracts, settling in crypto but tracking real-world asset prices. The Magnificent 7 — Alphabet, Amazon, Apple, Meta, Microsoft, Nvidia, and Tesla — represent the most-traded equity basket globally, making them a logical first tranche for a crypto exchange targeting equity-adjacent demand. The expansion follows OKX securing MiCA-compliant operating status in the EU, which opened the door to offering derivatives to retail customers across member states.
What's Next
Watch for OKX to broaden the X-Perps catalog to additional commodities or indices if early EU volume metrics justify it. Competitor responses from Binance and Coinbase's European derivatives desks will likely follow within the next quarter.
Gambling and leveraged derivatives involve significant risk of loss. Trade only what you can afford to lose.
Keep reading
WeeBet Weekly
The week's biggest market move, in 4 minutes.
Every Friday: the top Polymarket/Kalshi price shift, one regulatory story that actually matters, and one chart. No fluff, no promo. Free.
Free. Unsubscribe in one click. We'll never sell your email.